Abstract-The molecular mechanisms underlying seizure susceptibility in preeclampsia are unknown. We hypothesized that altered expression of distinct proteins in the cerebrospinal fluid (CSF) may reflect pathophysiological changes in the central nervous system that contribute to the neurological manifestations of severe preeclampsia. We obtained CSF samples from 13 patients with preeclampsia and 14 control patients during spinal anesthesia before delivery and analyzed them by SOMAscan, an aptamer-based proteomics platform for alterations in 1310 protein levels. Ingenuity Pathway Analysis was conducted to highlight relationships between preeclampsia-specific proteins found to be significantly altered. For 2 of the target proteins, we validated the difference in CSF concentrations by ELISA. SOMAscan revealed 82 proteins, whose expression levels were significantly different (P<0.05) in CSF from patients with preeclampsia versus controls. Principal component analysis achieved perfect separation of the preeclampsia and control groups in 2 dimensions. The differentially expressed proteins converge around 4 signaling molecules: TGF-β (transforming growth factor-β), VEGFA (vascular endothelial growth factor A), angiotensinogen, and IL-6 (interleukin-6). Within the TGF-β pathway, upregulation of activin A (301.6±47.4 versus 151.6±20.5 pg/mL; P=0.0074) and follistatin-related gene (5129±347 versus 3016±188 pg/mL; P<0.0001) in preeclampsia was confirmed by ELISA. In summary, signaling pathways important for vascular remodeling, inflammation, and neuronal growth, signaling, and electrophysiology were well represented among the proteins found to be altered in CSF in patients with preeclampsia. (Hypertension. 2018;72:219-226.
P reeclampsia, a pregnancy-specific complication that presents with maternal hypertension, and often proteinuria, is associated with increased risk of adverse fetal, neonatal, and maternal outcomes, including preterm birth, intrauterine growth restriction, perinatal death, thrombocytopenia, and acute renal or hepatic failure. 1 The pathogenesis of maternal syndrome of preeclampsia is thought to be because of excess inflammation and overexpression of circulating antiangiogenic factors sFlt1 and sEng (which sequester free VEGF [vascular endothelial growth factor] and TGF-β [transforming growth factor-β], respectively). [1] [2] [3] [4] [5] [6] [7] [8] [9] This antiangiogenic and proinflammatory environment leads to widespread endothelial dysfunction, which is a substrate for the common manifestations of preeclampsia-hypertension, proteinuria, and hematologic signs, such as thrombocytopenia. A model incorporating data from recent studies suggests that a decrease in free VEGF impairs nitric oxide synthesis by endothelial cells, which in turn promotes accumulation of oxidative stress, damages key capillary beds, such as the glomerulus, and enhances sensitivity to vasoconstrictors. 10 Preeclampsia is named for its potential to manifest with seizures (referred to as eclampsia)-perhaps its most feared complication and a phenomenon lacking a clear mechanistic explanation. In addition to seizures, the central nervous system (CNS) manifestations of preeclampsia include headache, hyperexcitability, hyperreflexia, and visual disturbances. 11 These phenomena may or may not share molecular underpinnings with the endothelial dysregulation and oxidative stress, which have been observed in systems outside the CNS in preeclampsia. Clinical studies have suggested that cerebral edema is a prominent radiographic finding in most cases of eclampsia, and striking similarities exist between CNS manifestations of preeclampsia and the posterior reversible leukoencephalopathy syndrome. 12, 13 But the specific molecular pathways giving rise to a posterior reversible leukoencephalopathy syndromelike clinical picture and changing the excitability of neurons remain unknown. Cerebrospinal fluid (CSF) is produced from arterial blood by the choroid plexus (CP, specialized tufts of capillaries found in the lateral and fourth ventricles of the brain). Whereas blood is separated from the interstitium of the CNS by the highly impermeable blood-brain barrier, the CSF is in contact with neural tissue via a much more permeable layer (the glia limitans), allowing more direct exchange of molecules.
14 As such, the content of the CSF may affect the function of the brain and vice versa. CSF has proven to be a useful source of biomarkers to distinguish healthy versus diseased CNS in neurological disorders, such as Alzheimer and Parkinson diseases. 15, 16 We hypothesized that the content of the CSF may reflect metabolic disturbances, inflammatory states, or other pathological factors encountered by the brain in preeclampsia that may contribute to its neurological manifestations. Here, we report a comparison of the protein content of CSF from women with preeclampsia to that from matched control patients. Our approach made use of the SOMAscan proteomics platform (SomaLogic Inc, Boulder, CO): a single-stranded DNA aptamer technology that is achieving widespread use for its ability to capture >1300 proteins from a biological sample for quantitative analysis at a wide range of concentrations.
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Methods
Data that support the findings of this study are available from the corresponding author on reasonable request.
Human Subjects
This study was approved by the Beth Israel Deaconess Medical Center Committee on Clinical Investigations, and all participants gave written informed consent.
Women eligible for the study were >18 years of age and admitted either in spontaneous labor or for induction of labor or cesarean section for any indication. Exclusion criteria included fever and an anesthesia plan that did not include spinal injection. Diagnosis of preeclampsia was made according to criteria from the 2013 American College of Obstetricians and Gynecologists (ACOG) Task Force on Hypertension in Pregnancy: new onset of hypertension (systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg) after 20 weeks gestation, plus either proteinuria (defined as >300 mg for 24 hours, or protein/creatinine ratio >0.3) or any other systemic manifestation, including thrombocytopenia (<100 000 per µL), impaired liver function (transaminases more than twice normal), renal insufficiency unexplained by other causes (creatinine >1.1 mg/dL or a doubling from baseline), pulmonary edema, or new onset neurological symptoms (severe headache or blurry vision). At the time of administration of spinal anesthesia, 1 mL of CSF was collected from each patient and stored immediately at 4°C. Samples were stored on a long-term basis at −80°C. Intrathecal punctures were grossly atraumatic.
SOMAscan Assay
SOMAscan analysis (SomaLogic) using CSF samples was performed at the BIDMC Genomics, Proteomics, Bioinformatics, and Systems Biology Center according to the standard protocols for biological fluids from SomaLogic that have been described in detail previously. [17] [18] [19] [20] SOMAscan has been used previously to analyze human CSF. 21 CSF samples were run using the SOMAscan Assay Cells & Tissue Kit, 1.3k (SomaLogic number, 900-00009) following the recommended protocol from the manufacturer. In brief, 20 µL of sample from each patient was run at a 15% dilution in 1× serum diluent. Three provided kit controls and 1 no-protein buffer control were run in parallel with the CSF samples. Median normalization and calibration of the SOMAscan data, performed according to the standard quality control protocols at SomaLogic, demonstrated that all samples passed the established quality control criteria.
Bioinformatic Analysis
Box-and-whisker plots were generated from the log-transformed SOMAscan relative fluorescence unit data, and unpaired t test was performed using SOMAsuite V1.0 (SomaLogic). Heat maps of the most differentially expressed proteins were generated with GENE-E (Broad Institute, Cambridge, MA). Principal component analysis was performed using top 50 dysregulated analytes and illustrated using Pearson correlation in XLSTAT.
To assess for potential molecular pathways underlying the preeclampsia-specific CSF protein signature and to more precisely understand the complex interactions between the differentially expressed proteins, we performed functional category, canonical pathway, and interactive network analyses of the top 50 proteins using the Ingenuity Pathway Analysis software tool (IPA V01-04; Qiagen). A detailed description of Ingenuity Pathway Analysis is available at the Ingenuity Systems web site (http://www.ingenuity.com). Upstream regulator analysis in Ingenuity Pathway Analysis was applied to predict enrichment and activation status of upstream regulators of the proteins with differential expression in preeclampsia.
Immunoassays for FLRG and Activin A
Upregulation of follistatin-related gene (FLRG, also known as follistatin-like 3 or FSTL3) and activin A (encoded by inhibin A gene and is a homodimer of two βA chains) in CSF from women with preeclampsia was validated by ELISA, using commercially available kits (R&D Systems catalog number, DLFRG0, Minneapolis, MN; and Ansh Labs catalog number, AL-110, Webster, TX) per their published protocols. Briefly, samples and standards were applied to microtiter wells coated with an antibody specific to the target of interest; unbound sample was washed away; wells were incubated with an enzyme-linked antibody specific for the target protein; unbound enzyme-linked antibody was washed away; a substrate solution was added to the wells; and a chemical reaction resulted in development of color in proportion to the amount of target present in the sample initially added to the plate. For FLRG, CSF samples were diluted 1:10 before use; no dilution was used for activin A. Assay results were quantified by a microplate spectrophotometer that measured dual wavelength absorbance: test at 450 nm versus reference at 630 nm (BioRad, Hercules, CA). Of note, the activin A antibody pair used in the ELISA does not cross-react with inhibin A, inhibin B, activin B, or activin AB, and analyte recovery is not inhibited by the presence of follistatin, per product literature. Mean protein concentrations and SEM were calculated from ELISA results for CSF from women with preeclampsia versus control patients. Unpaired Student t test was applied to determine the statistical significance of the difference among these 2 groups using GraphPad Prism 7 software, and P values <0.05 were considered significant.
Results
CSF was collected from 14 controls and 14 preeclampsia subjects. One subject with clinical diagnosis of preeclampsia was excluded in the final analysis as chart review revealed that this subject had gestational hypertension and did not satisfy the updated ACOG criteria for preeclampsia. Demographic information from the 27 subjects whose CSF was included in final analysis is summarized in Table S1 in the online-only Data Supplement. All subjects were between the ages of 27 and 38 years and represent a variety of ethnicities. There were significantly more nulliparous women in the preeclampsia group compared with controls, and the average gestational age of subjects with preeclampsia was younger; neither of these findings is unexpected in a cohort of patients with preeclampsia. Each of the 13 preeclamptic patients had severe features of some type; those with neurological symptoms were of interest to this study, so aggregate demographics of this subgroup are also summarized (Table S2) . Some but not all preeclamptic patients in the study were treated with magnesium sulfate (for seizure prophylaxis) before collection of CSF.
SOMAscan analysis revealed 82 of 1310 proteins whose expression levels were significantly different (P<0.05) in CSF from preeclamptic patients versus controls (51 increased, 31 decreased). Figure 1A shows the 50 proteins with the greatest degree of differential expression comparing patients with preeclampsia to controls; the heat map highlights the relative minimum and maximum concentrations among patients for each protein. Among the patients with preeclampsia, the SOMAscan assay also revealed proteins whose expression levels varied depending on the presence or absence of neurological symptoms ( Figure 1B) , as shown by a heat map of the top 50 differentially expressed proteins comparing these groups.
Principal component analysis using the top 50 proteins comparing all patients with preeclampsia to controls reveals that the preeclampsia group accurately separates from the control group in 2 dimensions (Figure 2 ). The first principal component accounts for 30% of the variance and the second principal component for 14% of the variance.
The difference in expression level is illustrated quantitatively in Figure 3 associations with shared upstream regulatory proteins was particularly informative. The upstream regulator models that emerged from this analysis converged on TGF-β1, VEGFA, angiotensinogen, and IL-6 (interleukin-6), indicating that these signaling nodes are likely involved in the dysregulation of a sizeable portion of the top 50 proteins in the CSF signature for preeclampsia (Figure 4) . Using quantitative ELISA, we then validated the differential expression of 2 of the SOMAscan targets downstream of TGF-β that have been previously linked to preeclampsia: FSTL3 and activin A. Both of these proteins were detectable by ELISA at significantly higher levels in CSF from patients with preeclampsia than control patients, and the degree of change was comparable to that demonstrated by SOMAscan ( Figure 5 ).
Discussion
Using a SOMAscan proteomics assay, we identified 82 unique proteins whose expression levels in CSF differed significantly in patients with preeclampsia versus control pregnant patients. Our findings may have implications for the pathogenesis of the maternal syndrome of preeclampsia and in particular the neurological complications of preeclampsia. Many of these proteins have known functions tied to distinct physiological processes, such as neuronal survival, electrophysiology and cell-cell signaling, metabolism, inflammation, and vascular remodeling (Table S3) . [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Possible reasons for altered expression of CSF proteins in a disease state are numerous. Proteins reach the CSF from several sources: the plasma, via filtration or active transport through the CP; CP endothelial cells, which synthesize and secrete a cadre of proteins locally; and brain parenchyma, initiating reverse flux of proteins from the brain to CSF and out into plasma. 38 Therefore, changes in the concentration of CSF proteins may reflect parallel changes in arterial blood, may result from breakdown of the filtration apparatus of the CP, may arise from changes in protein production by CP endothelial cells, or may reflect events occurring in the brain parenchyma.
Several of the proteins we identified are well represented in prior studies of preeclampsia. The activin/inhibin signaling pathway has been implicated in preeclampsia by a genome-wide association scan, 39 as well as several studies demonstrating increased placental and maternal serum levels of activin A and FSTL3 in preeclampsia. [40] [41] [42] [43] The activins are members of the TGF-β superfamily; on interaction with various TGF-β receptors, a downstream signaling cascade modulates transcriptional regulation of various targets. Activin A has been implicated in a wide range of biological processes, including cellular proliferation and differentiation and promotion of neuronal survival. Recently, a group reported that exogenous activin A administered to pregnant mice recapitulated some features of preeclampsia, including hypertension and proteinuria, 44 and that small molecule inhibitors of the activin A-receptor complex attenuated these changes. 45 Activin A is functionally inhibited by FSTL3, which is expressed by placenta among many other tissues, and is also upregulated by astroglial cells in the setting of neuronal trauma. 46 Our SOMAscan detected increased protein concentrations of FSTL3 and activin A in the CSF of women with preeclampsia, which we validated by ELISA. The functional significance of these findings in CSF is unclear, but they raise the possibility that activin A signaling in the brain may contribute to the CNS manifestations of preeclampsia.
The proteases tPA (tissue-type plasminogen activator) and trypsin were also among the CSF proteins with the greatest differential expression; these proteins are known to regulate the composition of the extracellular matrix via their proteolytic activity in the perineuronal space. 29 Changes to the extracellular matrix can directly affect neuronal function if adhesive contacts between neurons are compromised, or via activation of cell-surface receptors on proteolytic events, and disruption of the balance between proteolytic proteins and protease inhibitors in the extracellular matrix is known to contribute to neurological disorders. 47, 48 Furthermore, epileptiform activity was noted in transgenic mice overexpressing a protease inhibitor that targets tPA and trypsin, 49 providing a compelling basis for potential roles of these proteins in the mechanisms underlying seizure susceptibility in preeclampsia.
The appearance of interleukin 1β in the top 20 proteins upregulated in patients with severe preeclampsia characterized by neurological symptoms is notable as this cytokine is implicated in other disorders characterized by neuroinflammation. 50, 51 Importantly, interleukin 1β as well as interleukin 8, which is also among the top 20 upregulated proteins, have been demonstrated to increase seizure susceptibility, providing strong support for the notion that neuroinflammatory cytokines play a key role in seizures. 52 Also among the target proteins discriminating preeclamptic patients with and without neurological symptoms was α-SNAP (α-soluble N-ethylmaleimide sensitive factor attachment protein), a structural protein that facilitates neuronal vesicle trafficking and the membrane fusion steps involved in neurotransmitter release. 53 Altered expression of α-SNAP has been associated with disorders of neurophysiology, including temporal lobe epilepsy. [54] [55] [56] [57] Our study has limitations. Although many patients had severe preeclampsia, none were eclamptic, so the CSF samples we studied do not reflect the full extent of CNS pathophysiology that can occur with preeclampsia. Furthermore, most of the subjects in the preeclampsia group had been treated with magnesium sulfate before CSF collection, which may affect CSF proteomes and confound our results in unpredictable ways because its mechanism of seizure prophylaxis is unknown. Similarly, some but not all subjects were in labor at the time of CSF collection, and it is unknown what effect (if any) labor has on the CSF proteome, particularly with respect to inflammatory markers. We also did not study subtypes of preeclampsia, such as term or early onset preeclampsia that may have distinct pathogenesis. 58 Our sample size was also limited, so the effects of several other clinical variables, such as ethnicity, body mass index, parity, and gestational age, similarly cannot be accounted for. 
Perspectives
We report here a protein signature in the CSF of women with preeclampsia. Physiological functions represented among the proteins upregulated or downregulated include vascular remodeling, inflammation, and neuronal growth, signaling, and electrophysiology. Several of the targets showing differential expression are well represented in prior studies of preeclampsia, including activin A and FSTL3, although the functional significance of these proteins in the neurological manifestations of preeclampsia is unknown. Future work will help determine which changes reflect primary insults versus collateral damage and compensatory modulation. What Is New?
Sources of Funding
• SOMAscan is particularly suited for studying pathogenesis of a complex, multifactorial syndrome, such as preeclampsia, because it provides a more complete picture of multiple pathways involved.
• There were 82 proteins that were significantly altered in the cerebrospinal fluid from women with preeclampsia. Physiological functions represented among the proteins upregulated or downregulated, include neuronal growth, signaling, and electrophysiology, metabolism, inflammation, coagulation, and vasoactive factors.
• There was significant convergence of differentially expressed proteins around 4 signaling pathways: TGF-β (transforming growth factor-β1), VEGFA (vascular endothelial growth factor A), angiotensinogen, and IL-6 (interleukin-6).
What Is Relevant?
• In preeclampsia, a hypertensive complication of pregnancy, there are significant alterations in specific protein analytes in cerebrospinal fluid that may reflect metabolic disturbances, inflammatory states, or other pathological factors encountered by the brain.
• Future work will help determine which cerebrospinal fluid protein changes during preeclampsia reflect primary insults versus collateral damage and compensatory modulation.
Summary
We report here that signaling pathways important for vascular remodeling, inflammation, and neuronal growth, signaling, and electrophysiology were well represented among the proteins found to be altered in cerebrospinal fluid in patients with preeclampsia. Future work will help determine which changes reflect primary insults versus collateral damage and compensatory modulation.
Novelty and Significance
